Upperton Pharma Boosts Capacity After Nottingham Site Secures MHRA Nod
Upperton's new Nottingham facility gets MHRA approval, boosting GMP manufacturing capabilities.
Breaking News
Jul 17, 2024
Mrudula Kulkarni

Upperton Pharma Solutions celebrates a major milestone with
the successful MHRA inspection of its new 50,000 sq ft development and GMP
manufacturing facility in Nottingham, UK. The UK Government's regulatory
authority's approval underscores Upperton's achievement in swiftly completing
the facility's construction, commissioning, validation, and approval within
just 18 months. This accomplishment expands Upperton's capabilities to support
the development of oral, nasal, and pulmonary drug products, alongside providing
Phase I, II, and III clinical supplies.
Nikki Whitfield, CEO of Upperton Pharma Solutions, said in a
statement, “We are absolutely delighted to achieve this milestone. We have been
conducting manufacturing scale-up activities since the start of the year
following the installation of the larger-scale solid oral dosage form process
trains and this gives the green light for our GMP facility to support clients
right through to late-phase clinical manufacture and product registration”.
The MHRA's successful inspection empowers Upperton Pharma
Solutions to consolidate its R&D, GMP manufacturing, and commercialization
efforts at a single site. Recent investments in advanced process equipment,
including the Gerteis Mini-Pactor®, GEA Post Hoist Blender, O’Hara M50 Tablet
Coating System, and ZANASI 40 Capsule Filler, position Upperton to handle batch
sizes up to 250kg and a diverse range of dosage forms. This capability spans
solids, liquids, semi-solids, nasal and inhaled pharmaceuticals, covering
potent molecules and controlled drugs. The MHRA approval marks a pivotal step
in Upperton's evolution into an integrated CDMO.
Paul Kelsall, Director of Clinical Manufacturing, commented,
“This is a dedication to the tremendous hard work our colleagues have put in to
achieve the targets and aspirations of our business. We are looking forward to
working with our clients and offering services from early-stage development
through to late-stage clinical manufacture and Product Registration. These are
exciting times for Upperton as we continue to move forward and expand our
capabilities.”
Jon Austwick, Director of Quality & Compliance, further
added “This achievement is a culmination
of 18 months of hard work to commission a state-of-the-art facility and build
the rigorous quality and compliance processes to ensure the highest standards
of service to our customers.”